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1.  Introduction
Erectile dysfunction (ED) is defined as the inability to 
achieve or maintain erections sufficient for satisfactory 
sexual intercourse.1 It is a complex and, frequently, multi-
factorial disorder that leads to low self-esteem and de-
creased quality of life.2 In the past, the majority of ED 
cases were thought to be psychogenic in nature. Now, 
both organic and psychogenic factors are known to be 
involved in erectile function, and organic factors might 
explain approximately 70% of ED.3,4 Organic ED can be 
further classified into vascular (60–80%), neurogenic 
(10–20%), and hormonal causes (5–10%).5 Although many 
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There are 2 CME questions based on this article
of the pathophysiological mechanisms of ED remain to 
be determined, it is a treatable disorder and also an im-
portant risk factor for cardiovascular disease.2,6
Hypogonadism and ED are two independently dis-
tributed disorders. However, there is a degree of overlap 
between the two conditions.7 Men with hypogonadism 
can also have sexual symptoms such as loss of libido, ED, 
difficulty achieving orgasm, diminished sexual penile sen-
sation and other symptoms such as fatigue, lack of phys-
ical strength, impaired cognitive function, and depressed 
mood.8–10 In healthy, young, eugonadal men, serum 
total testosterone levels generally range from 300 ng/dL 
to 1050 ng/dL. Previous longitudinal and cross-sectional 
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studies have shown that a man’s serum testosterone 
levels decrease by 0.4–2.6% per year after the age of 
40.11–13 Because serum testosterone levels decline with 
advancing age, the impact of testosterone deficiency on 
aging men’s physical and sexual health have become an 
area of interest in recent years.8–10,14,15 However, it is 
often not easy to diagnose hypogonadism in clinical prac-
tice because of the nonspecific clinical symptoms and the 
lack of consensus with regard to the concentration of 
testosterone that constitutes eugonadal, hypogonadal or 
a borderline state.6
The introduction of phosphodiesterase type 5 (PDE-5) 
inhibitors for the treatment of ED has made a significant 
impact both in terms of clinical efficacy and increasing 
the awareness of the condition. However, approximately 
one-third of patients do not respond to PDE-5 inhibitors.16 
Moreover, patients taking nitrates cannot take PDE-5 in-
hibitors. In a previous meta-analysis, the overall response 
rate to testosterone therapy was 57% in patients with ED, 
64% in those with primary hypogonadism, and 44% in 
those with secondary hypogonadism.17 Several interven-
tional studies have also demonstrated that testosterone 
therapy could improve erectile function in hypogonadal 
men who have previously failed to respond to PDE-5 in-
hibitors alone.18,19 Thus, testosterone therapy might be 
a valuable option apart from PDE-5 inhibitors for men 
with ED. In this review, we summarize the evidence re-
lated to the role of testosterone in ED and discuss how 
ED with hypogonadism can be managed.
2.  The Role of Testosterone in Erectile 
Function
2.1.  Animal studies
A variety of experimental animal models (rat, dog, rabbit) 
have been used to assess the role of testosterone in erec-
tile function. Four major mechanisms from the studies 
of castrated animals have been described to explain how 
androgen deprivation could negatively impact erectile 
function.6,20–23 These mechanisms include: impairment of 
nitric oxide synthase (NOS) release; altered PDE-5 expres-
sion and activity; impaired cavernosal nerve function; and 
contribution to veno-occlusive disease in the penis.6,20–23
The important role of the NOS/cyclic guanosine mono-
phosphate pathway and PDE-5 in erectile function is 
well documented. Testosterones have been found to in-
fluence the expression of NOS isoforms in penile tissue.20 
In castrated animals, testosterone replacement restored 
erectile function and NOS expression in the corpora cav-
ernosa.20 In addition, the expression and activity of PDE-5 
is significantly decreased in castrated animals and can be 
restored with testosterone replacement.20 Moreover, cas-
tration in animals was demonstrated to induce marked 
structural changes in cavernosal nerves.20 These structural 
changes were reversed when the castrated animals were 
treated with testosterone.20 The medial preoptic area, 
which is the central area that induces erections in rats, 
is also testosterone-dependent.24
A significant reduction in trabecular smooth muscle 
content and a marked increase in connective deposition 
were found in the penis of castrated animals.20,25 Accu-
mulation of fat-containing cells in the subtunical region 
of the corpus cavernosum was also encountered in ani-
mals after castraction.20 The structure of the tunica albug-
inea also became thinner, with fewer elastic fibers and 
disorganization of collagen after castration.20,25 In penile 
corpus cavernosum, androgen deprivation has been hypo-
thesized to promote differentiation of stromal precursor 
cells into adipogenic lineage, producing fat-containing 
cells, thus altering erectile function.20 These findings sug-
gest that testosterone plays an important role in the 
overall structure of the penis and hypogonadism might 
contribute to venous leakage in the penis.21
2.2.  Human studies
In humans, the strongest evidence for the role of testo-
sterone in erectile function comes from studies of cas-
trated men. Overall, 58–100% of men suffered from 
partial or complete ED after castration.2 In a randomized, 
double-blind study of a gonadotropin-releasing hormone 
antagonist to induce acute and reversible testosterone 
deficiency in nine healthy young men for 6 weeks, a sig-
nificant decrease in libido and frequency of spontaneous 
erection were found. Both abnormalities were reversible 
after withdrawal of the gonadotropin-releasing hormone 
antagonist and restoration of normal serum testoster-
one levels.26 In another placebo-controlled trial of 10 
young healthy men, the duration of episodes of noctur-
nal erection was decreased in the five men who received 
luteinizing hormone-releasing hormone agonist compared 
with the five men who received placebo.27 Both studies 
suggest that castration of young healthy men may result 
in partial defects in sexually stimulated and nocturnal 
erection. Other studies of androgen ablation therapy in 
patients with prostate cancer also found that suppression 
of sexual desire, sexual intercourse, and nocturnal erec-
tion occurred in most patients.28,29
In addition to the evidence from the relationship be-
tween castration and ED, testosterone has been demon-
strated to have a vasodilator effect in humans.30,31 Webb 
and colleagues30 found that intracoronary administration 
of testosterone at physiological or greater concentrations 
induced coronary vasodilatation and increased coronary 
blood flow in men with coronary artery disease. Several 
studies also confirmed that testosterone therapy im-
proved the symptoms and threshold of angina in male 
patients, especially in those with hypogonadism.32–34
With regard to the effect of testosterone on penile 
blood flow, Aversa and colleagues35 found a strong di-
rect correlation between serum free testosterone levels 
and cavernous vasodilatation assessed by dynamic color 
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duplex ultrasound in 52 eugonadal men with ED. Becker 
et al.36 also found that plasma testosterone levels in the 
systemic and cavernous vasculature increased during 
penile tumescence after sexual arousal in both healthy 
men and patients with ED. However, the percentage in-
crease in testosterone levels from the flaccidity to tu-
mescence stages of erection was less pronounced in 
men with ED.
Stoleru and colleagues37 used positron emission to-
mography to evaluate brain activity during visually evoked 
sexual arousal in young healthy men. They found that the 
paralimbic area was activated during sexual arousal and 
correlated positively with the increase in plasma testo-
sterone levels. This preliminary study may provide us 
with evidence of testosterone’s effect on sexual function 
at the level of the higher center of the nervous system. 
However, further investigations are needed to clarify the 
effects of testosterone on erectile function in humans.
Metabolic syndrome is a diagnostic category based 
on a cluster of cardiovascular risk factors (hyperglycemia/
diabetes, abdominal obesity, hypertriglyceridemia, low 
high-density lipoprotein cholesterol, and hypertension), 
which is characterized by insulin resistance and shown 
to increase morbidity and mortality.13 Previous longitudi-
nal studies have found that low serum testosterone lev-
els are independent risk factors for the development of 
metabolic syndrome and diabetes mellitus.38–40 Because 
both metabolic syndrome and diabetes mellitus are im-
portant risk factors for ED,4,5 this could be important evi-
dence to support the relationship between testosterone 
and ED.
3.  Prevalence of Hypogonadism in 
Men With ED
As men age, the risk of developing hypogonadism and 
ED increase, especially after the age of 40.4,13,41 In 
Taiwan, the prevalence of ED increased from 8.2% in men 
aged 40–49 years to 34.4% in those aged ≥ 70 years. The 
overall prevalence of ED in Taiwanese men aged over 40 
was 17.7%.4 Because there is no universal consensus on 
the definition of hypogonadism, the overall prevalence 
of hypogonadism in Taiwanese men aged over 40 has 
been reported to range from 12% to 33%.13,41 If serum 
total testosterone level below 300 ng/dL is used to define 
hypogonadism, then the prevalence of hypogonadism 
increased from 16.5% in men aged 40–49 years to 37.2% 
in those aged ≥ 70 years.13
In previous reports, the prevalence of hypogonadism 
in men with ED varied widely from 1.7% to 35%.2,23 The 
wide variation may be due to the different populations 
studied, the different definitions of hypogonadism and ED 
used, and different methodologies.2,23 Most available 
studies failed to demonstrate a significant correlation 
between serum testosterone levels and erectile func-
tion.2,23 However, most of the men included in those 
studies were either eugonadal or mildly hypogonadal. 
In men with more severe hypogonadism, there might 
be a relationship between serum testosterone levels 
and ED.2,23
In castrated rats, erectile function is significantly and 
positively correlated with serum testosterone levels in 
a dose-dependent manner up to a critical threshold as 
low as 10–12% of normal physiological concentration. 
Above this level, there is no further correlation with erec-
tile function.42 In previous studies of testosterone ther-
apy in hypogonadal men, the effects of testosterone on 
sexual function are also dose-dependent up to a certain 
serum level at which they are maximum. Below this 
threshold, sexual function is impaired. This threshold level 
is close to the lower limit of the normal adult range, and 
is consistent within an individual, but markedly variable 
between individuals.43 Overall, serum total testosterone 
levels below 7 nmol/L (200 ng/dL) are most associated 
with impairment of sexual function.43 In a recent epide-
miologic study of men aged over 50 years, Zitzmann et al.44 
found that the testosterone-induced prevalence of loss 
of libido or loss of vigor increased below a total testo-
sterone level of 15 nmol/L (430 ng/dL). But in ED, the 
prevalence only increased when total testosterone level 
was below 8 nmol/L (230 ng/dL), after controlling for 
other covariates.
Some studies have proposed that a total testos-
terone level below 300 ng/dL can be considered a thresh-
old for hypogonadism.9,14 However, the level of serum 
testosterone considered normal or sufficient for men’s 
health is still unknown and may vary among individuals 
and in different tissues of the same person.13 Because 
the threshold level of serum testosterone for ED seems 
to be much lower than for hypogonadism, it might be 
one reason why some studies did not find a significant 
association between hypogonadism and ED, especially 
when they included mostly men with mild hypogonad-
ism.2,23,43 Some clinicians have suggested that hypogonad-
ism in men with lower total testosterone levels should 
be confirmed by testing the level of free testosterone or 
bioavailable testosterone, on the basis that the concen-
trations of free testosterone and bioavailable testoster-
one might correlate better with the biological activities 
of androgen.9,10,13 In a previous community study of 
aging Taiwanese men, only serum free testosterone and 
bioavailable testosterone levels, not total testosterone 
levels, were found to be significantly associated with ED 
severity.45
4.  Testosterone Therapy in ED
Testosterone therapy has been shown to improve erec-
tile function, especially in hypogonadal men.17,46 Jain 
et al.17 performed the first meta-analysis to evaluate the 
effect of testosterone therapy on ED. They found that 
the overall response rate to testosterone therapy was 
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57% in men with ED, 64% in those with primary hypo-
gonadism, and 44% in those with secondary hypogonad-
ism.17 In another meta-analysis, testosterone therapy 
was found to moderately improve the number of noctur-
nal erections, sexual thoughts and motivation, number 
of successful episodes of intercourse, and scores of 
erectile function and overall sexual satisfaction in men 
with an average serum total testosterone level at base-
line below 12 nmol/L (346 ng/dL).46 However, testoster-
one therapy had no effect on erectile function in eugonadal 
men compared to placebo.46 In addition, the effect of 
testosterone therapy on erectile function, but not on 
libido, was inversely related to mean baseline testo-
sterone level.46 In a double-blind, randomized, placebo-
controlled 3-month study, Chiang and colleagues47 found 
that testosterone therapy improved different sexual func-
tions in hypogonadal men, and the effect is mainly through 
restoration of erectile function. In a long-term study of 
testosterone therapy in 123 hypogonadal men, Wang 
et al.48 found that sexual desire, sexual activity, and sat-
isfaction with erection were all significantly improved 
after 6 months of treatment and were maintained up to 
42 months.
Testosterone therapy has also been demonstrated to 
facilitate the effect of PDE-5 inhibitors on men with ED, 
especially in those who failed to respond to PDE-5 inhib-
itors alone.18,19,49 Aversa and colleagues49 found that 
short-term testosterone therapy in hypogonadal men 
with arteriogenic ED increased arterial inflow to cavern-
ous arteries and improved erectile response to sildena-
fil. Shabsigh et al.18 reported that within 4 weeks in men 
with hypogonadism and ED, testosterone therapy con-
verted sildenafil non-responders to responders. Hwang 
et al.19 found that in hypogonadal men with ED who 
failed to respond to sildenafil, one-third responded to 
testosterone therapy alone, and another third responded 
to sildenafil after normalization of serum testosterone 
level.
As an increasing number of studies have indicated 
that testosterone therapy is a viable option to treat ED 
in hypogonadal men, the most recent guidelines of the 
European Association of Urology have recommended 
that all men presenting with ED should receive evalua-
tion of serum testosterone levels.50 In addition, treating 
hypogonadism is recommended before the initiation of 
PDE-5 inhibitor treatment.50 Morgentaler also suggested 
that ED in hypogonadal men should be treated with tes-
tosterone therapy first, rather than with PDE-5 inhibitors, 
because additional benefits on other physical symptoms 
might occur and good responders can be cured without 
the need to plan for intercourse, as is necessary with 
PDE-5 inhibitors.51 If erections remain insufficient after 
3 months of testosterone therapy alone, then the com-
bination of testosterone and PDE-5 inhibitor may be 
suggested.7 However, it is important to evaluate the po-
tential risks and benefits before deciding on testosterone 
therapy in hypogonadal men with ED, and to monitor 
the efficacy and safety during treatment. The absolute 
contraindications of testosterone therapy include pros-
tate cancer, breast cancer, significant erythrocytosis 
(hematocrit > 52%), untreated obstructive sleep apnea, 
and untreated severe congestive heart failure. The rela-
tive contraindications include high risk of developing pros-
tate cancer and severe lower urinary tract symptoms.9,10
During testosterone therapy, safety monitoring pa-
rameters for adverse effects should include breast ex-
amination, digital rectal examination, serum testosterone 
level, serum prostate-specific antigen level, complete 
blood count with hematocrit, and metabolic panel. 
These should all be evaluated at baseline, at 3, 6 and 12 
months, and then annually.9,10 There are several com-
mercial formulations currently available for testosterone 
therapy. However, there is no evidence that clinical re-
sponse differs among the different formulations em-
ployed. Rather, the choice should be based on discussion 
with the patient and decided according to the patient’s 
preference, pharmacokinetics, treatment burden, and 
costs.9 Because oral methylated testosterones have po-
tential for liver toxicity, several societies have recom-
mended that they should no longer be prescribed.8–10,15
5.  Conclusion
Available data suggest that testosterone plays an impor-
tant role in erectile function. In men with ED, screening for 
hypogonadism is necessary and testosterone therapy may 
be considered as first-line therapy for ED in hypo gonadal 
men. However, the minimal threshold level of serum 
testosterone necessary to maintain erectile function is 
still unknown, and may vary among individuals. In addi-
tion, the potential risks and benefits of testosterone ther-
apy should be assessed and discussed with patients before 
treatment, and the safety and efficacy of testosterone 
therapy should be monitored regularly during treatment.
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